30 September - 2 October 2014 in Reims, Champagne-Ardenne France.
Join us in October for the 7th European Forum for Industrial Biotechnology and the Biobased Economy, for an insight into this exciting and rapidly evolving landscape and be part of the process of building a stronger more sustainable biobased economy.
The agenda is now confirmed, with over 15 countries represented on the conference programme and plenary highlights including:
- Setting the policy agenda with representatives of the French ministry and the European Commission.
- Feedstocks for the Future; what does the shale gas boom mean for Europe's transition to a biobased economy?
- Defining the value chain for a selection of biobased materials, including perspectives from key players and a panel discussion
- Plus the closing panel defining opportunities for improving the sustainability profile of industrial production
Taking place, in association with IAR, EuropaBio and Smithers Rapra will build on the success of EFIB 2013, making the most of the event's new format to draw an even larger crowd of biobased economy professionals. Read more on what you can expect here
View the full agenda for 2014 >>
View the pre-conference workshops on Blue Biotechnology and the Woodbased Bioeconomy >>
Check out the Advisory Board who guided the EFIB 2014 programme >>
Speakers from all levels of the value chain presenting at EFIB!
We are pleased to bring you an unrivalled line up of over 80 speakers, speaking across the 7 tracks, plenary programmes and pre-conference workshops, including VP level representatives from leading companies DSM and Arkema, plus CEOs of successful SMEs Cristal Union, Photanol, MetGen and more! Also with panellists joining us from Coca Cola | Unilever | Natureworks | DSM | Suedzucker | European Commission | Roundtable for Sustainable Biomaterials this is an event not to be missed!
New speaker confirmed for opening plenary session
Daniele Ferrari, CEO, Versalis SpA and Chairman, Matrica SpA will join the opening plenary session, alongside Shell and European Bioplastics to deliver his perspectives on opportunities and challenges of biobased chemistry. Mr Ferrari is well placed in the chemical industry and is also board member of CEFIC and Vice-President of Federchimica for European Affairs and Economy, and will bring much expertise to this high level session.
View the speaking listing here >>
EFIB is taking place during Biorefinery week
This year's event partners IAR are running a biorefinery week in Reims, during the week of EFIB. The week will consist of tours to local biorefinery plants, workshops and one day meetings in the heart of the Champagne-Ardenne region. View more information on what will be taking place in Reims in October and how you can be a part of it here >>
What happened at EFIB 2013?
The European Forum for Industrial Biotechnology and the Biobased Economy (EFIB) opened to a record delegation last year in Brussels at The Square. Then in its 6th year, EFIB had successfully made the transformation from a small specialised conference to a market leading, pan European flagship event for the vibrant and dynamic sector of Europe's bioeconomy.
The event took place during the first ever European Biotech Week, and had 700 delegates in attendance all on site to gain access to the market place of 45 exhibitors and 20 technology showcase presentations. They took place alongside a formidable programme of senior leaders including Belgian Ministers, a record number of European policy makers and CEOs from Galactic, Ecover and several other multinational companies.
Read more about EFIB's record year
Read the full review on what happened at EFIB 2013
Global Partnerships and Alliances Key to Industrial Biotechnology Futures
Key drivers behind new partnerships and alliances in industrial biotechnology will be the need to access raw materials and technology at the required cost and amount and exposure to diversified markets, according to new forecasts by Smithers Rapra.
The Future of Alliances and Partnerships in Industrial Biotechnology to 2023 contains details of the competitive biotechnology landscape and quantitative forecasts until 2023, as well as details of emerging markets. It includes extensive primary research, and reveals what will be essential for the dynamic biotechnology industry in years to come.
Read more here
Keep up with the conversation and follow us on LinkedIn and Twitter
|In association with: |